The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization.
Jae Seung LeeHong Jun ChoiBeom Kyung KimJun Yong ParkDo Young KimSang Hoon AhnKwang-Hyub HanSong Ee BaekEun Yong ChungMi-Suk ParkMyeong Jin KimHyungjin RheeSeung-Up KimPublished in: Gut and liver (2021)
Response evaluations that use the mRECIST provide more accurate prognoses than those that use the RECIST 1.1 in HCC patients treated with TARE.